Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Vivos continues to retire secured debt without using cash.</li><li>Twelve exchange agreements, consummated September 2, 2026, retired $2.861 million of principal under the June 2025 Streeterville note in exchange for 11,445,080 common shares.</li><li>Including the August 4 exchange, Vivos has retired ~$6.1 million of principal since early August, following a further $975,000 of redemption obligations satisfied in stock between December 2025 and May 2026.</li></ul>

Vivos continues to retire secured debt without using cash.Twelve exchange agreements, consummated September 2, 2026, retired $2.861 million of principal under the June 2025 Streeterville note in exchange for 11,445,080 common shares.Including the August 4 exchange, Vivos has retired ~$6.1 million of principal since early August, following a further $975,000 of redemption obligations satisfied in stock between December 2025 and May 2026.

VVOS: Cash-Free Deleveraging Should Shift Focus to Operational Execution

Vivos Therapeutics

VVOS: Cash-Free Deleveraging Should Shift Focus to Operational Execution